Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure

被引：20
作者：
Imamura, Teruhiko [1 ]
Kinugawa, Koichiro [2 ]
机构：
[1] Univ Tokyo, Dept Therapeut Strategy Heart Failure, Grad Sch Med, Tokyo 1138655, Japan
[2] Toyama Univ, Dept Internal Med 2, Toyama 9300194, Japan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 01期
基金：
日本学术振兴会;
关键词：
heart failure; congestion; chronic kidney disease; hyponatremia; CHRONIC-KIDNEY-DISEASE; EFFECTIVELY PREDICT RESPONSE; WATER CHANNEL; CLINICAL-COURSE; ORAL TOLVAPTAN; EXCRETION; HYPONATREMIA; SODIUM; RADIOIMMUNOASSAY; RESPONSIVENESS;
D O I：
10.3390/ijms17010105
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Aquaporin-2, a member of the aquaporin family, is an arginine vasopressin-regulated water channel expressed in the renal collecting duct, and a promising marker of the concentrating and diluting ability of the kidney. The arginine vasopressin type-2 antagonist, tolvaptan, is a new-generation diuretic; it is especially indicated in patients with decompensated heart failure refractory to conventional diuretics. However, the ideal responders to tolvaptan have not yet been identified, and non-responders experience worse clinical courses despite treatment with tolvaptan. Urine aquaporin-2 has recently been demonstrated as a promising predictor of response to tolvaptan. We here validated aquaporin-2-guided tolvaptan therapy in patients with decompensated heart failure. Long-term efficacy of tolvaptan treatment in the responders defined by aquaporin-2 needs to be validated in the future prospective study.
引用
收藏
页数：7
相关论文
共 40 条
1234